文献速递淋巴瘤

体外扩增LAK细胞联合利妥昔单抗维持治疗滤泡性淋巴瘤安全且可能延缓疾病进展

Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression.
PubMed 文献 · Br J Haematol · 2020-03-04

这项开放、前瞻性、II期单臂研究在20例滤泡性淋巴瘤缓解期患者中,评估利妥昔单抗维持期间输注体外扩增的淋巴因子激活的杀伤(LAK)细胞的安全性和疗效。中位随访59.4个月时85%患者无进展,无治疗相关严重不良事件,生活质量改善。结论认为该联合方案长期安全,但需更大规模研究确认疗效。

要点

  • 体外扩增LAK细胞联合利妥昔单抗维持治疗在滤泡性淋巴瘤缓解期患者中长期安全性良好。
  • 中位随访59.4个月,85%患者保持无进展,仅3例进展,无死亡。
  • 所有周期中rhIL-2刺激后NK、LAK和ADCC活性显著增加,利妥昔单抗显著增强细胞毒活性。

核心结论

  • 滤泡性淋巴瘤缓解期患者接受体外扩增LAK细胞联合利妥昔单抗维持治疗长期看来是安全的,并可能延缓疾病进展。

研究设计与样本

  • 开放、前瞻性、II期、单臂研究,纳入20例滤泡性淋巴瘤缓解期患者,在利妥昔单抗维持治疗后输注体外扩增的LAK细胞,随访5年。

主要发现

  • 维持治疗结束时外周血细胞表型无明显变化。
  • 所有周期中重组人IL-2刺激后单核细胞的NK、LAK和ADCC活性显著增加,利妥昔单抗显著增强细胞毒活性。
  • 无患者因治疗中止,无治疗相关严重不良事件。
  • 随访结束时3例患者进展;中位(四分位距)随访59.4(43.8-70.9)个月,85%患者保持无进展,无死亡发生。
  • 研究期间生活质量改善。

临床怎么用

  • 对于滤泡性淋巴瘤缓解期患者,利妥昔单抗维持期间联合体外扩增LAK细胞可能是一种安全且有望延缓进展的策略。

局限性

  • 单臂、小样本II期研究,疗效需更大规模研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anti-cluster of differentiation 20 (CD20) monoclonal antibodies (mAbs) have shown promise in follicular lymphoma (FL) as post-induction therapy, by enhancing antibody-dependent cellular cytotoxicity (ADCC). However, cytotoxic cells are reduced after this treatment. We hypothesised that ex vivo expanded lymphokine-activated killer (LAK) cells administered to FL-remission patients are safe and improve anti-CD20 efficacy. This open, prospective, phase II, single-arm study assessed safety and efficacy of ex vivo expanded LAK cells in 20 FL-remission patients following rituximab maintenance. Mononuclear cells were obtained in odd rituximab cycles and stimulated with interleukin 2 (IL-2) for 8 weeks, after which >5 × 108 LAK cells were injected. Patients were followed-up for 5 years. At the end of maintenance, peripheral blood cells phenotype had not changed markedly. Natural killer, LAK and ADCC activities of mononuclear cells increased significantly after recombinant human IL-2 (rhIL-2) stimulation in all cycles. Rituximab significantly enhanced cytotoxic activity. No patients discontinued treatment. There were no treatment-related serious adverse events. Three patients had progressed by the end of follow-up. After a median (interquartile range) follow-up of 59.4 (43.8-70.9) months, 85% of patients remained progression free. No deaths occurred. Quality-of-life improved throughout the study. Post-induction LAK cells with rituximab seem safe in the long term. Larger studies are warranted to confirm efficacy.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. López-Díaz de Cerio A, García-Muñoz R, Pena E, et al. Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression. Br J Haematol. 2020. PMID: 32130737. doi:10.1111/bjh.16474

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。